MA52967B1 - Composés antagonistes du pcsk9 - Google Patents

Composés antagonistes du pcsk9

Info

Publication number
MA52967B1
MA52967B1 MA52967A MA52967A MA52967B1 MA 52967 B1 MA52967 B1 MA 52967B1 MA 52967 A MA52967 A MA 52967A MA 52967 A MA52967 A MA 52967A MA 52967 B1 MA52967 B1 MA 52967B1
Authority
MA
Morocco
Prior art keywords
compounds
antagonist compounds
pcsk9 antagonist
pcsk9
formula
Prior art date
Application number
MA52967A
Other languages
English (en)
Other versions
MA52967A (fr
Inventor
Fa-Xiang Ding
Chengwei WU
Elisabetta Bianchi
Harold B. Wood
Hubert B. Josien
Thomas Joseph Tucker
Angela Dawn KEREKES
Ling Tong
Abbas M. Walji
Anilkumar G. NAIR
Danila Branca
Yusheng Xiong
Sookhee Nicole Ha
Jian Liu
Sobhana Babu Boga
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of MA52967A publication Critical patent/MA52967A/fr
Publication of MA52967B1 publication Critical patent/MA52967B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des composés de formule I, ou un sel de ceux-ci, formule dans laquelle A, B, D, X, R1, R2 et R8 sont tels que définis dans la description, lesdits composés présentant des propriétés antagonistes au niveau du PCSK9. L'invention concerne également des formulations pharmaceutiques comprenant les composés de formule I ou leurs sels, et des procédés de traitement de maladies cardiovasculaires et d'états liés à l'activité du PCSK9, par exemple l'athérosclérose, l'hypercholestérolémie, la coronaropathie, le syndrome métabolique, le syndrome coronarien aigu ou les maladies cardiovasculaires et cardiométaboliques associées.
MA52967A 2018-06-21 2019-06-20 Composés antagonistes du pcsk9 MA52967B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687913P 2018-06-21 2018-06-21
EP19739801.9A EP3810626B1 (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9
PCT/US2019/038155 WO2019246349A1 (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9

Publications (2)

Publication Number Publication Date
MA52967A MA52967A (fr) 2021-04-28
MA52967B1 true MA52967B1 (fr) 2025-09-30

Family

ID=67263083

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52967A MA52967B1 (fr) 2018-06-21 2019-06-20 Composés antagonistes du pcsk9

Country Status (38)

Country Link
US (3) US11427616B2 (fr)
EP (2) EP4660303A3 (fr)
JP (3) JP7112531B2 (fr)
KR (2) KR20250161677A (fr)
CN (2) CN112313243B (fr)
AR (1) AR115597A1 (fr)
AU (2) AU2019290163C1 (fr)
BR (1) BR112020025274A8 (fr)
CA (1) CA3102629A1 (fr)
CL (2) CL2020003257A1 (fr)
CO (1) CO2021000456A2 (fr)
CR (1) CR20210031A (fr)
DK (1) DK3810626T3 (fr)
DO (1) DOP2020000250A (fr)
EA (1) EA202190086A1 (fr)
EC (1) ECSP21003643A (fr)
ES (1) ES3047399T3 (fr)
FI (1) FI3810626T3 (fr)
GE (2) GEP20237506B (fr)
HR (1) HRP20251302T1 (fr)
HU (1) HUE073367T2 (fr)
IL (2) IL279363B2 (fr)
JO (1) JOP20190150A1 (fr)
LT (1) LT3810626T (fr)
MA (1) MA52967B1 (fr)
MD (1) MD3810626T2 (fr)
MX (1) MX2020013726A (fr)
NI (1) NI202000101A (fr)
PE (1) PE20211584A1 (fr)
PH (1) PH12020552187A1 (fr)
PL (1) PL3810626T3 (fr)
PT (1) PT3810626T (fr)
RS (1) RS67338B1 (fr)
SG (1) SG11202012451WA (fr)
SI (1) SI3810626T1 (fr)
TW (1) TWI840376B (fr)
UA (1) UA129467C2 (fr)
WO (1) WO2019246349A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100558932B1 (ko) * 2005-04-21 2006-03-10 주식회사 엠제이스마트 테크놀러지 다공성 세라믹 분리막 제조방법과, 이에 의해 제조되어진 다공성 세라믹 분리막
EP4091624A1 (fr) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Analogues d'hepcidine et leurs utilisations
CA2949215C (fr) 2014-05-16 2023-03-14 Protagonist Therapeutics, Inc. Antagonistes du peptide thioether .alpha.4.beta.7 integrine
SG10201810154WA (en) 2014-07-17 2018-12-28 Protagonist Therapeutics Inc Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
WO2018022937A1 (fr) 2016-07-27 2018-02-01 Protagonist Therapeutics, Inc. Inhibiteurs peptidiques de l'interleukine-23 et leur utilisation dans le traitement des maladies inflammatoires
WO2019157268A1 (fr) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Mimétiques d'hepcidine conjugués
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
EP3810129B1 (fr) 2018-06-21 2023-08-16 Merck Sharp & Dohme LLC Composés bicycliques antagonistes de pcsk9
EP3810178A4 (fr) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
WO2019246405A1 (fr) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
ES3015132T3 (en) 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
EP4021919A1 (fr) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds
SMT202500254T1 (it) 2020-01-15 2025-09-12 Janssen Biotech Inc Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie
MX2022008740A (es) 2020-01-15 2022-09-23 Janssen Biotech Inc Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
US11932705B2 (en) 2020-12-18 2024-03-19 Merck Sharp & Dohme Llc Cyclic polypeptides for PCSK9 inhibition
KR20240034224A (ko) 2021-07-14 2024-03-13 얀센 바이오테크 인코포레이티드 인터류킨-23 수용체의 지질화된 펩티드 억제제
MX2024002146A (es) * 2021-08-19 2024-03-08 Merck Sharp & Dohme Llc Compuestos para el tratamiento de afecciones relacionadas con la actividad de pcsk9.
SI4540267T1 (sl) 2022-06-15 2026-07-31 Merck Sharp & Dohme Llc Ciklični peptidi za ujetje interlevkina-1 beta
JP7866141B2 (ja) * 2022-08-17 2026-05-26 メルク・シャープ・アンド・ドーム・エルエルシー Ｐｃｓｋ９阻害薬の結晶形態、組成物及び使用
WO2024259310A2 (fr) * 2023-06-15 2024-12-19 Merck Sharp & Dohme Llc Composés antagonistes de pcsk9 perméables passifs
IL328311A (en) 2023-11-14 2026-07-01 Merck Sharp & Dohme Llc Cyclic peptide for capturing Interleukin-1 Beta
AU2024401721A1 (en) 2023-12-15 2026-07-16 Merck Sharp & Dohme Llc A cyclic peptide il-1beta trap for the treatment of atherosclerosis and inflammatory disorders
WO2025242221A1 (fr) * 2024-05-24 2025-11-27 上海翰森生物医药科技有限公司 Nouvelle chaîne latérale modifiée, son procédé de préparation et son utilisation
WO2025264781A1 (fr) * 2024-06-18 2025-12-26 Kemira Oy J Agents de cationisation pour saccharides et procédés
WO2026019622A1 (fr) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Formes cristallines d'un cyclictétrapeptide et procédés de préparation
WO2026019624A1 (fr) * 2024-07-15 2026-01-22 Merck Sharp & Dohme Llc Synthèse d'oligopeptides cycliques
WO2026032253A1 (fr) * 2024-08-06 2026-02-12 石药集团中奇制药技术（石家庄）有限公司 Analogue de peptide cyclique, son procédé de préparation et son utilisation
WO2026034639A1 (fr) * 2024-08-09 2026-02-12 株式会社Spin Wave Excipient soluble pour la synthèse de peptides et procédé de synthèse l'utilisant
CN119930471A (zh) * 2024-12-31 2025-05-06 苏州默迪夫生物科技有限公司 Mk-a的制备方法、所用的中间体及其合成方法
CN122464947A (zh) * 2025-01-25 2026-07-28 深圳市祥根生物有限公司 一种环肽类pcsk9抑制剂和用途

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393046A (en) 1981-01-30 1983-07-12 Merck & Co., Inc. Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency
US4656269A (en) 1986-04-15 1987-04-07 Kissei Pharmaceutical Co., Ltd. Histidine derivatives
DE3841520A1 (de) 1988-12-09 1990-06-13 Hoechst Ag Enzymhemmende harnstoffderivate von dipeptiden, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
US5104869A (en) 1989-10-11 1992-04-14 American Cyanamid Company Renin inhibitors
US5114937A (en) 1989-11-28 1992-05-19 Warner-Lambert Company Renin inhibiting nonpeptides
US5095119A (en) 1990-03-08 1992-03-10 American Home Products Corporation Renin inhibitors
DE69819311T2 (de) 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
AU6691798A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
WO1998039344A1 (fr) 1997-03-07 1998-09-11 Metabasis Therapeutics, Inc. Nouveaux composes de purine inhibiteurs de fructose-1,6-biophasphatase
CZ297264B6 (cs) 1998-09-09 2006-10-11 Metabasis Therapeutics, Inc. Nové heteroaromatické inhibitory fruktóza-1,6-bisfosfatázy
CA2415742A1 (fr) 2000-07-25 2002-01-31 Merck & Co., Inc. Indoles n-substitues utiles pour le traitement du diabete
US6852738B2 (en) 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
WO2004019869A2 (fr) 2002-08-29 2004-03-11 Merck & Co., Inc. Indoles presentant un effet antidiabetique
CA2495943C (fr) 2002-08-29 2009-07-21 Merck & Co., Inc. Indoles a activite antidiabetique
CA2512879A1 (fr) 2003-01-17 2004-08-12 Soumya P. Sahoo Derives de n-cyclohexylaminocarbonyl benzenesulfonamide
CA2667894A1 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
EP2174343A1 (fr) 2007-06-28 2010-04-14 Semiconductor Energy Laboratory Co, Ltd. Procédé de fabrication d'un dispositif à semi-conducteurs
US20100179173A1 (en) 2007-06-28 2010-07-15 Daniel Guay Substituted fused pyrimidines as antagonists of gpr105 activity
US20110301079A1 (en) 2007-09-21 2011-12-08 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Neuromedin u receptor agonists and uses thereof
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
US7928189B2 (en) 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009148605A2 (fr) 2008-06-04 2009-12-10 Isis Pharmaceuticals, Inc. Procédés pour traiter une hypercholestérolémie
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
US20120219558A1 (en) 2009-09-25 2012-08-30 Yan Ni Antagonists of pcsk9
CA2813049A1 (fr) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Compstatine modifiee ayant des proprietes de stabilite et de liaison ameliorees
NZ612544A (en) 2010-12-28 2015-04-24 Cadila Healthcare Ltd Heterocyclic compounds suitable for the treatment of dyslipidemia
MX2013009258A (es) * 2011-02-11 2013-10-17 Novartis Ag Antagonistas de pcsk9.
WO2012131504A1 (fr) 2011-03-02 2012-10-04 Pfizer Inc. Vaccin à base de pcsk9
WO2012168491A1 (fr) * 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
KR20140041747A (ko) 2011-06-20 2014-04-04 제넨테크, 인크. Pcsk9-결합 폴리펩티드 및 사용 방법
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
EP2814501A4 (fr) 2012-03-13 2016-03-02 Tensive Controls Inc Analogues de mélanocortine présentant une activité et un transport améliorés
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
EP2684865A1 (fr) 2012-07-13 2014-01-15 Heidelberg Pharma GmbH Procédés de synthèse de bloc de construction dýamatoxine et amatoxine
WO2014140210A1 (fr) 2013-03-14 2014-09-18 Pieris Ag Nouvelles protéines de fixation pour la pcsk9
JP2016512825A (ja) 2013-03-15 2016-05-09 シファ・バイオメディカル・コーポレイションＳｈｉｆａ Ｂｉｏｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 抗プロタンパク質転換酵素サブチリシン／ケキシン９型（抗ｐｃｓｋ９）化合物および心血管疾患の治療および／または予防におけるその使用方法
MX373298B (es) 2013-10-11 2020-05-20 Sanofi Biotechnology Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
BR122021025449B1 (pt) 2014-06-12 2024-02-15 Ra Pharmaceuticals, Inc Composto, polipeptídeo e composição compreendendo o mesmo
WO2016119067A1 (fr) 2015-01-30 2016-08-04 Pronasci Inc. Peptides dérivés du domaine catalytique du gène pcsk9 humain et utilisations de ceux-ci pour favoriser l'activité du récepteur des ldl
RU2747877C2 (ru) 2016-01-13 2021-05-17 Ново Нордиск А/С Аналоги эфр(а) с заместителями - жирными кислотами
CN107286158A (zh) 2016-03-30 2017-10-24 中国科学院上海药物研究所 苯基[a]吲哚[2,3-g]并喹嗪类化合物、其制备方法、药物组合物及其应用
EP3442991A4 (fr) 2016-04-15 2019-11-20 RA Pharmaceuticals, Inc. Peptides de liaison à ras et méthodes d'utilisation
AU2017281332A1 (en) 2016-06-24 2018-12-20 F. Hoffmann-La Roche Ag Compositions and methods for treating cardiovascular disease
US10577357B2 (en) 2016-09-19 2020-03-03 The Texas A&M University System Inhibitors of LDLR-PCSK9 protein-protein interaction and methods of their use
CN109284823B (zh) 2017-04-20 2020-08-04 上海寒武纪信息科技有限公司 一种运算装置及相关产品
CN107158002B (zh) * 2017-07-01 2020-06-16 维亚生物科技(上海)有限公司 苄撑巴比妥类化合物在作为pcsk9拮抗剂和降低低密度脂蛋白中的应用
WO2019246405A1 (fr) 2018-06-21 2019-12-26 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
ES3015132T3 (en) 2018-06-21 2025-04-29 Ucb Holdings Inc Cyclic polypeptides for pcsk9 inhibition
KR20250161677A (ko) 2018-06-21 2025-11-17 머크 샤프 앤드 돔 엘엘씨 Pcsk9 길항제 화합물
US11814444B2 (en) 2018-06-21 2023-11-14 Ra Pharmaceuticals, Inc. Cyclic polypeptides for PCSK9 inhibition
EP3810178A4 (fr) 2018-06-21 2022-05-04 Merck Sharp & Dohme Corp. Polypeptides cycliques pour l'inhibition de la pcsk9
EP3810129B1 (fr) 2018-06-21 2023-08-16 Merck Sharp & Dohme LLC Composés bicycliques antagonistes de pcsk9
EP4021919A1 (fr) 2019-08-30 2022-07-06 Merck Sharp & Dohme Corp. Composés antagonistes du pcsk9
US12577259B2 (en) 2019-12-20 2026-03-17 Merck Sharp & Dohme Llc PCSK9 antagonist compounds

Also Published As

Publication number Publication date
SI3810626T1 (sl) 2025-12-31
JP2022141879A (ja) 2022-09-29
JP7112531B2 (ja) 2022-08-03
BR112020025274A2 (pt) 2021-03-09
HRP20251302T1 (hr) 2025-12-19
AU2022259744B2 (en) 2024-07-11
US12209145B2 (en) 2025-01-28
ECSP21003643A (es) 2021-02-26
ES3047399T3 (en) 2025-12-03
US20190389909A1 (en) 2019-12-26
MA52967A (fr) 2021-04-28
IL279363B1 (en) 2025-08-01
WO2019246349A1 (fr) 2019-12-26
SG11202012451WA (en) 2021-01-28
EA202190086A1 (ru) 2021-05-18
EP4660303A2 (fr) 2025-12-10
PL3810626T3 (pl) 2025-12-22
IL321719A (en) 2025-08-01
AU2022259744A1 (en) 2022-12-01
CR20210031A (es) 2021-02-11
PT3810626T (pt) 2025-10-15
DK3810626T3 (da) 2025-08-18
EP3810626A1 (fr) 2021-04-28
US20250206781A1 (en) 2025-06-26
AU2019290163A1 (en) 2021-01-07
CN112313243A (zh) 2021-02-02
US11427616B2 (en) 2022-08-30
KR20250161677A (ko) 2025-11-17
EP3810626B1 (fr) 2025-07-23
MX2020013726A (es) 2021-03-02
CL2020003257A1 (es) 2021-07-23
MD3810626T2 (ro) 2025-12-31
RS67338B1 (sr) 2025-11-28
PH12020552187A1 (en) 2021-07-26
CN112313243B (zh) 2025-09-02
CL2022000027A1 (es) 2022-08-19
TW202019950A (zh) 2020-06-01
JP2025041712A (ja) 2025-03-26
BR112020025274A8 (pt) 2023-02-14
CN121130044A (zh) 2025-12-16
JP7855670B2 (ja) 2026-05-08
AU2019290163B2 (en) 2022-08-04
JP2021522311A (ja) 2021-08-30
NI202000101A (es) 2021-05-28
CO2021000456A2 (es) 2021-01-29
KR20210024035A (ko) 2021-03-04
DOP2020000250A (es) 2021-02-28
AR115597A1 (es) 2021-02-03
KR102884527B1 (ko) 2025-11-13
HUE073367T2 (hu) 2026-01-28
US20230159592A1 (en) 2023-05-25
CA3102629A1 (fr) 2019-12-26
GEP20237506B (en) 2023-05-25
EP4660303A3 (fr) 2026-02-25
PE20211584A1 (es) 2021-08-18
FI3810626T3 (fi) 2025-10-21
TWI840376B (zh) 2024-05-01
UA129467C2 (uk) 2025-05-07
JP7607615B2 (ja) 2024-12-27
LT3810626T (lt) 2025-11-10
WO2019246349A8 (fr) 2021-02-04
JOP20190150A1 (ar) 2019-12-21
IL279363B2 (en) 2025-12-01
IL279363A (en) 2021-01-31
AU2019290163C1 (en) 2022-11-03
GEAP202215540A (en) 2022-12-12

Similar Documents

Publication Publication Date Title
PH12020552187A1 (en) Pcsk9 antagonist compounds
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
MX380928B (es) Inhibidores de kras g12c.
EP2613782A4 (fr) Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012162254A8 (fr) Inhibiteurs de l'activité lrrk2 kinase
WO2016106331A8 (fr) Inhibiteurs d'idh1 mutants utiles pour traiter le cancer
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
EP4631505A3 (fr) Formes cristallines et formes salines d'un inhibiteur de kinase
HK1223917A1 (zh) 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物
NZ605444A (en) Salt and solvates of a tetrahydroisoquinoline derivative
MX376283B (es) Compuestos de imidazopiridazina.
EA201792071A3 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
PH12017500029A1 (en) 4,5-dihydroisoxazole derivatives as nampt inhibitors
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
ZA202108034B (en) Crystalline salt forms of a kinase inhibitor
MX379704B (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
WO2016165205A8 (fr) Nouvel inhibiteur de kinase bcr-abl
AR119864A1 (es) Compuestos antagonistas de pcsk9
WO2024259310A3 (fr) Composés antagonistes de pcsk9 perméables passifs
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7